Publications

Journal articles:

1. Ray, S.K., Mukherjee, S. Clinical aspect of male breast cancer: a burgeoning and unaddressed issue. Mol Biol Rep 52, 452 (2025). https://doi.org/10.1007/s11033-025-10558-4

2. Masarkar, N., Ray, S. K., Maity, B., Kanwar, J. R., & Mukherjee, S. (2024). Shadow beneath the lamp: Pediatric response to different variants of SARS-COV-2: A pandemic dilemma and Unmasking the enigma. Journal of Academy of Biomedical Sciences, 1(2).

3. Ray, S. K., & Mukherjee, S. (2024). Exploring new COVID-19 incertitude: JN.1 variant- JN.1: The Queer Bird among Omicron sublineages. Infectious Disorders - Drug Targets, 25(1). https://doi.org/10.2174/0118715265304215240530073446

4. Rai S, Ray SK, Kanwar JR, Mukherjee S. Exosome-based therapeutics: Advancing drug delivery for neurodegenerative diseases. Mol Cell Neurosci. 2025 Mar 22;133:104004. doi: 10.1016/j.mcn.2025.104004. Epub ahead of print. PMID: 40122271. 

5. Kumar, M., Sengar, A. S., Lye, A., Kumar, P., Mukherjee, S., Kumar, D., Das, P., Chatterjee, S., Stewart, A., & Maity, B. (2025). FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms. Redox Biology, 80, 103527. https://doi.org/10.1016/j.redox.2025.103527

6. Masarkar, Neha, Pal, Maynak, Roy, Mithun, Yadav, Ashish K., Pandya, Bharati, Lokhande, Suryabhan, Kanwar, Jagat R., Ray, Suman Kumar and Mukherjee, Sukhes. " In-silico screening of bioactive compounds of Moringa oleifera as potential inhibitors targeting HIF-1α/VEGF/GLUT-1 pathway against breast cancer" Journal of Complementary and Integrative Medicine, vol. 22, no. 1, 2025, pp. 149-164. https://doi.org/10.1515/jcim-2024-0176 

7. Ray SK, Mukherjee S. New Insights into Reductive Stress Responses and its Clinical Relation in Cancer. Tissue and Cell. 2025;93:102736. doi:10.1016/j.tice.2025.102736

8. Kumar M, Sengar AS, Lye A, Kumar P, Mukherjee S, Kumar D, Das P, Chatterjee S, Stewart A, Maity B. FNDC5/irisin mitigates the cardiotoxic impacts of cancer chemotherapeutics by modulating ROS-dependent and -independent mechanisms. Redox Biol. 2025 Mar;80:103527. doi: 10.1016/j.redox.2025.103527. Epub 2025 Feb 4. PMID: 39923397; PMCID: PMC11850786. 

9. Ray SK, Mukherjee S. Mechanical factors in the breast cancer microenvironment: Emphasizing functional adaptation. Biochem Biophys Res Commun. 2025 May 19;771:152048. doi: 10.1016/j.bbrc.2025.152048. Epub ahead of print. PMID: 40412051. 

10. Ray SK, Mukherjee S. Clinical aspect of male breast cancer: a burgeoning and unaddressed issue. Mol Biol Rep. 2025 May 13;52(1):452. doi: 10.1007/s11033-025-10558-4. PMID: 40358767. 

Book Chapters:

1. Ray, S.K., Mukherjee, S. (2025). Hypoxia and Regulation of Cancer Cell Stemness. In: Mukherjee, S., Kanwar, J.R. (eds) Hypoxia and Tumor Microenvironment. Springer, Singapore. https://doi.org/10.1007/978-981-96-1016-7_8 

2. Ray, S.K., Mukherjee, S. (2025). Tumor Hypoxia: An Introduction. In: Mukherjee, S., Kanwar, J.R. (eds) Hypoxia and Tumor Microenvironment. Springer, Singapore. https://doi.org/10.1007/978-981-96-1016-7_1 

3. Singh, S., Kugaji, M.S., Ray, S.K., Shukla, K.K., Mukherjee, S. (2025). Incipient Role of Noncoding RNAs in Different Types of Cancer Hypoxia. In: Mukherjee, S., Kanwar, J.R. (eds) Hypoxia and Tumor Microenvironment. Springer, Singapore. https://doi.org/10.1007/978-981-96-1016-7_3 

4. Pathak, T., Ray, S. K., & Mukherjee, S. (2025). Metabolic regulation of CAR-T cell function by hypoxic tumor. In Hypoxia and Tumor Microenvironment: Implications for Cancer Therapy (pp. 77–95). https://doi.org/10.1007/978-981-96-1016-7_5

5. Ray, S. K., & Mukherjee, S. (2025). Regulation of angiogenesis by cancer hypoxia and role of hypoxia Inducible Factors with therapeutic Paradigm. In Hypoxia and Tumor Microenvironment: Implications for Cancer Therapy (pp. 131–148). https://doi.org/10.1007/978-981-96-1016-7_7

1. Ray, S. K., & Mukherjee, S. (2024b). Hyperoxic-hypoxic paradox: Breast cancer microenvironment and an innovative treatment strategy. Anti-Cancer Agents in Medicinal Chemistry, 24(10), 729–732. https://doi.org/10.2174/0118715206290816240220062545

2. Masarkar N, Ray S, Saleem Z, Mukherjee S. Potential anti-cancer activity of Moringa oleifera derived bio-active compounds targeting hypoxia-inducible factor-1 alpha in breast cancer. Journal of Complementary and Integrative Medicine. 2024;21(3): 282-294. https://doi.org/10.1515/jcim-2023-0182

3. Ray, S. K., & Mukherjee, S. (2024). A New-fangled COVID-19 Variant, Eris, Might be the One to Lookout in 2023 or far from Over. Infectious Disorders - Drug Targets, 24(6). https://doi.org/10.2174/0118715265276833240105110046

4. Ray, S. K., & Mukherjee, S. (2024b). Role of protein ubiquitination and HIF signaling in the evolution of hypoxic breast cancer. Current Pharmaceutical Biotechnology, 25(17), 2183–2185. https://doi.org/10.2174/0113892010292219240212065544

5. Pal, M., Bera, A., Masarkar, N., Upadhyay, A., Mukherjee, S., & Roy, M. (2024). Targeted chemo‐phototherapy in red light with novel doxorubicin and iron(III) complex‐functionalized gold nanoconjugate (Dox‐Fe@FA‐AuNPs). Chemistry - an Asian Journal. https://doi.org/10.1002/asia.202400616

6. Masarkar N, Pal M, Roy M, Yadav A, Pandya B, Lokhande S, Kanwar J, Ray S, Mukherjee S. In-silico screening of bioactive compounds of Moringa oleifera as potential inhibitors targeting HIF-1α/VEGF/GLUT-1 pathway against breast cancer. Journal of Complementary and Integrative Medicine. 2025;22(1): 149-164. https://doi.org/10.1515/jcim-2024-0176

7. Ray SK, Mukherjee S. Limning of HIF-2 and HIF-3 in the Tumor Microenvironment: Developing Concepts for the Treatment of Hypoxic Cancer. Current Molecular Medicine. 2024 May. DOI: 10.2174/0115665240303179240427071748. PMID: 38766832.

8. Mukherjee S, Masarkar N, Ray S, Kanwar J. Hypoxia plays a pivotal role in regulating cellular stemness, tumor microenvironment, and the fate of breast cancer cells in experimental models. Clinica Chimica Acta. 2024 May 1;558:118907.

9. Ray, S.K., Mukherjee, S. Molecular perspectives on systemic priming and concomitant immunity in colorectal carcinoma. J Egypt Natl Canc Inst 36, 7 (2024). https://doi.org/10.1186/s43046-024-00211-9

10. Ray SK, Mukherjee S. Breast cancer stem cells as novel biomarkers. Clinica Chimica Acta 2024;557:117855. https://doi.org/10.1016/j.cca.2024.117855.

11. Ray SK, Jayashankar E, Kotnis A, Mukherjee S. Oxidative versus Reductive Stress in Breast Cancer Development and Cellular Mechanism of Alleviation: A Current Perspective with Anti-breast Cancer Drug Resistance. Current Molecular Medicine 2023;24:205–16. https://doi.org/10.2174/1566524023666230309112751.

12. Ray SK, Mukherjee S. Detection of genetic and epigenetic markers in neurodegenerative disorders. Elsevier eBooks, 2023, p. 137–54. https://doi.org/10.1016/b978-0-323-95539-3.00009-0.

13. Pal M, Bera A, Masarkar N, Upadhyay A, Mukherjee S, Roy M. Targeted Chemo-Phototherapy in Red Light with Novel Doxorubicin and Iron(III) Complex-Functionalized Gold Nanoconjugate (Dox-Fe@FA-AuNPs). Chem Asian J. 2024 Sep 16;19(18):e202400616. doi: 10.1002/asia.202400616. Epub 2024 Aug 21. PMID: 38923831. 

14. Pal M, Upadhyay A, Masarkar N, Bera A, Mukherjee S, Roy M. Folate-assisted targeted photocytotoxicity of red-light-activable iron(III) complex co-functionalized gold nanoconjugates (Fe@FA-AuNPs) against HeLa and triple-negative MDA-MB-231 cancer cells. *Dalton Trans*. 2024 Jan 30;53(5):2108-2119. doi: 10.1039/d3dt03581f. PMID: 38180438. 

1. Ray, S. K., & Mukherjee, S. (2023). Innovative nanomaterials for targeting hypoxia to improve treatment for triple-negative breast cancer. Recent Patents on Biotechnology, 18(4), 269–272. https://doi.org/10.2174/0118722083270521231027074157

2. Ray, S. K., & Mukherjee, S. (2023a). Emerging role of ferroptosis in breast cancer: characteristics, therapy, and translational implications for the present and future. Current Molecular Medicine, 24(12), 1470–1482. https://doi.org/10.2174/1566524023666230913105735

3. Singh, P., Tripathi, M. K., Khare, R., Jhade, S. K., Khan, A., Mukherjee, S., Ahirwar, S. S., Ray, S. K., Shrivastava, R., & Kotnis, A. L. (2023). Phytoconstitutents from Indian medicinal plants show therapeutic potential to combat COVID-19 by bind to SARS CoV-2 Main Protease (Mpro). Research Square (Research Square). https://doi.org/10.21203/rs.3.rs-3498252/v1

4. Ray SK, Mukherjee S. Human monkeypox virus: current state of knowledge and implications for the imminent days. Infectious Disorders - Drug Targets 2023;23. https://doi.org/10.2174/1871526523666230427144755

5. Ray SK, Mukherjee S. Immunological Facet and Inception after Post-COVID-19 Vaccination. Infectious Disorders - Drug Targets 2023;23. https://doi.org/10.2174/1871526523666230406100146.

6. Ray SK, Mukherjee S. Can the New BA.2.75 Sub-variant Lead To One More COVID-19 Wave? Infectious Disorders - Drug Targets 2023;23. https://doi.org/10.2174/1871526523666230302103609.

7. Ray SK, Mukherjee S. Memory reflections of the Microbiota-Gut and oligodendrocyte axis. CNS & Neurological Disorders - Drug Targets 2023;23:971–83. https://doi.org/10.2174/0118715273256132230921103333.

8. Mukherjee S, Ray SK, Jadhav AA, Wakode SL. Multi-level analysis of HBA1C in diagnosis and prognosis of diabetic patients. Current Diabetes Reviews 2023;20. https://doi.org/10.2174/0115733998262501231015051317.

9. Mukherjee S, Yadav P, Ray SK, Jadhav AA, Wakode SL. Clinical Risk Assessment and Comparison of Bias between Laboratory Methods for Estimation of HbA1c for Glycated Hemoglobin in Hyperglycemic Patients. Current Diabetes Reviews 2023;20. https://doi.org/10.2174/0115733998257140231011102518.

10. Ray SK, Mukherjee S. Innovation and patenting activities during COVID-19 and advancement of biochemical and molecular diagnosis in the Post-COVID-19 era. Recent Patents on Biotechnology 2023;18:210–26. https://doi.org/10.2174/0118722083262217230921042127.

11. Das K, Basak M, Mahata T, Biswas S, Mukherjee S, Kumar P, Moniruzzaman M, Stewart A, Maity B. Cardiac RGS7 and RGS11 drive TGFβ1-dependent liver damage following chemotherapy exposure. *FASEB J*. 2023 Aug;37(8):e23064. doi: 10.1096/fj.202300094R. PMID: 37440271. 

1. Mukherjee S, Ray SK. Neuropharmacology of Alcohol Addiction with Special Emphasis on Proteomic Approaches for Identification of Novel Therapeutic Targets. Current Neuropharmacology 2022;21:119–32. https://doi.org/10.2174/1570159x20666220811092906.

2. Ray SK, Mukherjee S. Assimilating Epigenetics and Transcriptomics for the Identification of Prognostic Novel Biomarkers and Imminent Targets in Colorectal Carcinoma with Therapeutic Potential. Current Molecular Medicine 2022;23:784–98. https://doi.org/10.2174/1566524022666220511123104.

3. Ray SK, Mukherjee S. Hypoxia-Inducible Factors-Based Single Nucleotide Polymorphism in Breast Cancer with More Cancer Susceptibility. Current Molecular Medicine 2022;23:285–8. https://doi.org/10.2174/1566524022666220513124853.

4. Mukherjee S, Ray SK. Interplay between SARS-CoV-2 and Cancer: Plausible Risk Factors, Cellular Immune Responses, Cancer Directed Therapy- Current Challenges. Infectious Disorders - Drug Targets 2022;23. https://doi.org/10.2174/1871526523666221028162406.

5. Mukherjee S, Ray SK. A new year, newfangled COVID-19 variant B.1.640.2 (IHU): What we know so far? Infectious Disorders - Drug Targets 2022;23. https://doi.org/10.2174/1871526522666220831101802.

6. Mukherjee S, Ray SK. Divulging Incipient SARS-CoV-2 Delta (B.1.617.2) Variant: Possible Interference with Global Scenario. Infectious Disorders - Drug Targets 2022;23. https://doi.org/10.2174/1871526522666220606092243.

7. Ray SK, Mukherjee S. The Emergence of Omicron SARS-CoV-2 Variant (B.1.1.529): The Latest Episode in the COVID-19 Pandemic with a Global Riposte. Infectious Disorders - Drug Targets 2022;22. https://doi.org/10.2174/1871526522666220422110415.

8. Mukherjee S, Ray SK. A New Wave of COVID-19 in 2021 with Unique Genetic Characters - Present Global Scenario and Beholding Onwards. Infectious Disorders - Drug Targets 2022;22. https://doi.org/10.2174/1871526522666220401101818.

9. Ray SK, Mukherjee S. Mesenchymal Stem Cells Derived from Umbilical Cord Blood Having Excellent Stemness Properties with Therapeutic Benefits - a New Era in Cancer Treatment. Current Stem Cell Research & Therapy 2022;17:328–38. https://doi.org/10.2174/1574888x17666220425102154.

10. Mukherjee S, Ray SK. Altered Expression of TRIM Proteins - Inimical Outcome and Inimitable Oncogenic Function in Breast Cancer with Diverse Carcinogenic Hallmarks. Current Molecular Medicine 2022;23:44–53. https://doi.org/10.2174/1566524022666220111122450.

11. Mukherjee S, Ray SK, Kotnis A, Kanwar JR. Elucidating the Role of Cardiac Biomarkers in COVID-19: A Narrative Evaluation with Clinical Standpoints and a Pragmatic Approach for Therapeutics. Current Cardiology Reviews 2022;18. https://doi.org/10.2174/1573403x18666220222144002.

12. Mukherjee S, Ray SK. Inborn Errors of Metabolism Screening in Neonates: Current Perspective with Diagnosis and Therapy. Current Pediatric Reviews 2022;18:274–85. https://doi.org/10.2174/1573396318666220404194452.

13. Mukherjee S, Kotnis A, Ray SK, Vaidyanathan K, Singh S, Mittal R. Current Scenario of Clinical Diagnosis to Identify Inborn Errors of Metabolism with Precision Profiling for Expanded Screening in Infancy in a Resource-limited Setting. Current Pediatric Reviews 2022;19:34–47. https://doi.org/10.2174/1573396318666220404113732.

14. Ray SK, Mukherjee S. Piwi-interacting RNAs (piRNAs) and Colorectal Carcinoma: Emerging Non-invasive diagnostic Biomarkers with Potential Therapeutic Target Based Clinical Implications. Current Molecular Medicine 2022;23:300–11. https://doi.org/10.2174/1566524022666220124102616.

15. Mukherjee S, Ray SK. Challenges in engendering herd immunity to SARS-COV-2 infection: possibly impossible but plausibile. Infectious Disorders - Drug Targets 2022;22. https://doi.org/10.2174/1871526522666220117153838.

16. Ray SK, Mukherjee S. Directing hypoxic tumor microenvironment and HIF to illuminate cancer immunotherapy’s existing prospects and challenges in drug targets. Current Drug Targets 2022;23:471–85. https://doi.org/10.2174/1389450123666220111114649.